Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Epidemiology and management options for colorectal cancer in children.

Paediatric drugs

Saab R, Furman WL.
PMID: 18454570
Paediatr Drugs. 2008;10(3):177-92. doi: 10.2165/00148581-200810030-00006.

Colorectal carcinoma (CRC), although primarily a disease of adulthood, accounts for 2% of malignancies in adolescents and has been reported in children as young as 9 months of age. Our knowledge of CRC in pediatrics is based on a...

Cite
Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs. 2008;10(3):177-92doi: 10.2165/00148581-200810030-00006.
Saab, R., & Furman, W. L. (2008). Epidemiology and management options for colorectal cancer in children. Paediatric drugs, 10(3), 177-92. https://doi.org/10.2165/00148581-200810030-00006
Saab, Raya, and Furman, Wayne L. "Epidemiology and management options for colorectal cancer in children." Paediatric drugs vol. 10,3 (2008): 177-92. doi: https://doi.org/10.2165/00148581-200810030-00006
Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs. 2008;10(3):177-92. doi: 10.2165/00148581-200810030-00006. PMID: 18454570.
Copy Download .nbib Format: NLM
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019.

The Lancet. Oncology

[No authors listed]
PMID: 34871551
Lancet Oncol. 2022 Jan;23(1):27-52. doi: 10.1016/S1470-2045(21)00581-7. Epub 2021 Dec 03.

BACKGROUND: In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in...

Cite
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol. 2021;23(1):27-52doi: 10.1016/S1470-2045(21)00581-7.
(2022). The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. Oncology, 23(1), 27-52. https://doi.org/10.1016/S1470-2045(21)00581-7
"The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019." The Lancet. Oncology vol. 23,1 (2022): 27-52. doi: https://doi.org/10.1016/S1470-2045(21)00581-7
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol. 2022 Jan;23(1):27-52. doi: 10.1016/S1470-2045(21)00581-7. Epub 2021 Dec 03. PMID: 34871551; PMCID: PMC8716339.
Copy Download .nbib Format: NLM
Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models.

Pediatric blood & cancer

Janke LJ, Kim J, Payton MA, Jenkins DA, Cai X, Finch ER, Liu Y, Relling MV, Karol SE.
PMID: 34121318
Pediatr Blood Cancer. 2021 Oct;68(10):e29183. doi: 10.1002/pbc.29183. Epub 2021 Jun 14.

BACKGROUND: Osteonecrosis is a devastating side effect of acute lymphoblastic leukemia (ALL) therapy. Associations between bone density loss and osteonecrosis have sparked interest in using bisphosphonates to reduce this complication.PROCEDURE: We assessed the impact of zoledronic acid (ZA) on...

Cite
Janke LJ, Kim J, Payton MA, et al. Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models. Pediatr Blood Cancer. 2021;68(10):e29183doi: 10.1002/pbc.29183.
Janke, L. J., Kim, J., Payton, M. A., Jenkins, D. A., Cai, X., Finch, E. R., Liu, Y., Relling, M. V., & Karol, S. E. (2021). Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models. Pediatric blood & cancer, 68(10), e29183. https://doi.org/10.1002/pbc.29183
Janke, Laura J, et al. "Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models." Pediatric blood & cancer vol. 68,10 (2021): e29183. doi: https://doi.org/10.1002/pbc.29183
Janke LJ, Kim J, Payton MA, Jenkins DA, Cai X, Finch ER, Liu Y, Relling MV, Karol SE. Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models. Pediatr Blood Cancer. 2021 Oct;68(10):e29183. doi: 10.1002/pbc.29183. Epub 2021 Jun 14. PMID: 34121318; PMCID: PMC8384719.
Copy Download .nbib Format: NLM
Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management.

Cancer

Nguyen HTK, Terao MA, Green DM, Pui CH, Inaba H.
PMID: 34031876
Cancer. 2021 Sep 01;127(17):3067-3081. doi: 10.1002/cncr.33609. Epub 2021 May 25.

Acute lymphoblastic leukemia (ALL) in children and adolescents can involve the testes at diagnosis or upon relapse. The testes were long considered pharmacologic sanctuary sites, presumably because of the blood-testis barrier, which prevents the entry of large-molecular-weight compounds into...

Cite
Nguyen HTK, Terao MA, Green DM, et al. Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management. Cancer. 2021;127(17):3067-3081doi: 10.1002/cncr.33609.
Nguyen, H. T. K., Terao, M. A., Green, D. M., Pui, C. H., & Inaba, H. (2021). Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management. Cancer, 127(17), 3067-3081. https://doi.org/10.1002/cncr.33609
Nguyen, Hoa Thi Kim, et al. "Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management." Cancer vol. 127,17 (2021): 3067-3081. doi: https://doi.org/10.1002/cncr.33609
Nguyen HTK, Terao MA, Green DM, Pui CH, Inaba H. Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management. Cancer. 2021 Sep 01;127(17):3067-3081. doi: 10.1002/cncr.33609. Epub 2021 May 25. PMID: 34031876.
Copy Download .nbib Format: NLM
Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy.

Pediatric blood & cancer

Finch ER, Janke LJ, Li L, Payton MA, Jenkins DA, Crews KR, Relling MV, Karol SE.
PMID: 34866312
Pediatr Blood Cancer. 2021 Dec 05;e29490. doi: 10.1002/pbc.29490. Epub 2021 Dec 05.

INTRODUCTION: There are clinical reports that the incorporation of dasatinib may increase the frequency of osteonecrosis in acute lymphoblastic leukemia (ALL) treatment regimens. No rigorous testing of this hypothesis is available to guide clinicians.METHODS: We tested whether oral dasatinib...

Cite
Finch ER, Janke LJ, Li L, et al. Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. Pediatr Blood Cancer. 2021;e29490doi: 10.1002/pbc.29490.
Finch, E. R., Janke, L. J., Li, L., Payton, M. A., Jenkins, D. A., Crews, K. R., Relling, M. V., & Karol, S. E. (2021). Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. Pediatric blood & cancer, e29490. https://doi.org/10.1002/pbc.29490
Finch, Emily R, et al. "Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy." Pediatric blood & cancer vol. (2021): e29490. doi: https://doi.org/10.1002/pbc.29490
Finch ER, Janke LJ, Li L, Payton MA, Jenkins DA, Crews KR, Relling MV, Karol SE. Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. Pediatr Blood Cancer. 2021 Dec 05;e29490. doi: 10.1002/pbc.29490. Epub 2021 Dec 05. PMID: 34866312.
Copy Download .nbib Format: NLM
Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.

Cancer

Trendowski MR, Baedke JL, Sapkota Y, Travis LB, Zhang X, El Charif O, Wheeler HE, Leisenring WM, Robison LL, Hudson MM, Morton LM, Oeffinger KC, Howell RM, Armstrong GT, Bhatia S, Dolan ME.
PMID: 34286861
Cancer. 2021 Nov 01;127(21):4091-4102. doi: 10.1002/cncr.33775. Epub 2021 Jul 19.

BACKGROUND: Cranial radiation therapy (CRT) is associated with ototoxicity, which manifests as hearing loss and tinnitus. The authors sought to identify clinical determinants and genetic risk factors for ototoxicity among adult survivors of pediatric cancer treated with CRT.METHODS: Logistic...

Cite
Trendowski MR, Baedke JL, Sapkota Y, et al. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer. 2021;127(21):4091-4102doi: 10.1002/cncr.33775.
Trendowski, M. R., Baedke, J. L., Sapkota, Y., Travis, L. B., Zhang, X., El Charif, O., Wheeler, H. E., Leisenring, W. M., Robison, L. L., Hudson, M. M., Morton, L. M., Oeffinger, K. C., Howell, R. M., Armstrong, G. T., Bhatia, S., & Dolan, M. E. (2021). Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer, 127(21), 4091-4102. https://doi.org/10.1002/cncr.33775
Trendowski, Matthew R, et al. "Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort." Cancer vol. 127,21 (2021): 4091-4102. doi: https://doi.org/10.1002/cncr.33775
Trendowski MR, Baedke JL, Sapkota Y, Travis LB, Zhang X, El Charif O, Wheeler HE, Leisenring WM, Robison LL, Hudson MM, Morton LM, Oeffinger KC, Howell RM, Armstrong GT, Bhatia S, Dolan ME. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer. 2021 Nov 01;127(21):4091-4102. doi: 10.1002/cncr.33775. Epub 2021 Jul 19. PMID: 34286861; PMCID: PMC8516694.
Copy Download .nbib Format: NLM
Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences.

Cancer

Chemaitilly W, Li Z, Brinkman TM, Delaney A, Huang S, Bjornard KL, Lam CG, Wilson CL, Barnes N, Clark KL, Krasin MJ, Metzger ML, Sheyn A, Bishop MW, Sabin ND, Howell RM, Helmig S, Shulkin BL, Triplett BM, Pui CH, Gajjar A, Srivastava DK, Green DM, Armstrong GT, Robison LL, Hudson MM, Ness KK, Sklar CA, Krull KR.
PMID: 34643950
Cancer. 2021 Oct 13; doi: 10.1002/cncr.33969. Epub 2021 Oct 13.

BACKGROUND: Data on primary hypothyroidism and its long-term impact on the health, cognition, and quality of life (QOL) of childhood cancer survivors are limited. This study examined the prevalence of and risk factors for primary hypothyroidism and its associations...

Cite
Chemaitilly W, Li Z, Brinkman TM, et al. Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. Cancer. 2021;doi: 10.1002/cncr.33969.
Chemaitilly, W., Li, Z., Brinkman, T. M., Delaney, A., Huang, S., Bjornard, K. L., Lam, C. G., Wilson, C. L., Barnes, N., Clark, K. L., Krasin, M. J., Metzger, M. L., Sheyn, A., Bishop, M. W., Sabin, N. D., Howell, R. M., Helmig, S., Shulkin, B. L., Triplett, B. M., Pui, C. H., Gajjar, A., Srivastava, D. K., Green, D. M., Armstrong, G. T., Robison, L. L., Hudson, M. M., Ness, K. K., Sklar, C. A., & Krull, K. R. (2021). Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. Cancer, . https://doi.org/10.1002/cncr.33969
Chemaitilly, Wassim, et al. "Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33969
Chemaitilly W, Li Z, Brinkman TM, Delaney A, Huang S, Bjornard KL, Lam CG, Wilson CL, Barnes N, Clark KL, Krasin MJ, Metzger ML, Sheyn A, Bishop MW, Sabin ND, Howell RM, Helmig S, Shulkin BL, Triplett BM, Pui CH, Gajjar A, Srivastava DK, Green DM, Armstrong GT, Robison LL, Hudson MM, Ness KK, Sklar CA, Krull KR. Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. Cancer. 2021 Oct 13; doi: 10.1002/cncr.33969. Epub 2021 Oct 13. PMID: 34643950.
Copy Download .nbib Format: NLM
Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy.

Pediatric blood & cancer

Finch ER, Janke LJ, Li L, Payton MA, Jenkins DA, Crews KR, Relling MV, Karol SE.
PMID: 34866312
Pediatr Blood Cancer. 2021 Dec 05;e29490. doi: 10.1002/pbc.29490. Epub 2021 Dec 05.

INTRODUCTION: There are clinical reports that the incorporation of dasatinib may increase the frequency of osteonecrosis in acute lymphoblastic leukemia (ALL) treatment regimens. No rigorous testing of this hypothesis is available to guide clinicians.METHODS: We tested whether oral dasatinib...

Cite
Finch ER, Janke LJ, Li L, et al. Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. Pediatr Blood Cancer. 2021;e29490doi: 10.1002/pbc.29490.
Finch, E. R., Janke, L. J., Li, L., Payton, M. A., Jenkins, D. A., Crews, K. R., Relling, M. V., & Karol, S. E. (2021). Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. Pediatric blood & cancer, e29490. https://doi.org/10.1002/pbc.29490
Finch, Emily R, et al. "Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy." Pediatric blood & cancer vol. (2021): e29490. doi: https://doi.org/10.1002/pbc.29490
Finch ER, Janke LJ, Li L, Payton MA, Jenkins DA, Crews KR, Relling MV, Karol SE. Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. Pediatr Blood Cancer. 2021 Dec 05;e29490. doi: 10.1002/pbc.29490. Epub 2021 Dec 05. PMID: 34866312.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries